Hyphen BioMed Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 100

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

Hyphen BioMed General Information

Description

Operator of a technical and innovative scientific company intended to propose a full line of diagnostic and research reagents to be distributed worldwide. The company offers medical, pharmaceutical research and hospital laboratories innovative tools for research and specialized biological diagnostics for thrombosis, hemostasis and auto-immune diseases, enabling the company to conceive, manufacture, market and develop research and biomedical in vitro diagnostic reagents for the exploration of thrombosis.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Corporate Office
  • 155 Rue D Eragny
  • 95000 Neuville sur Oise
  • France
+33 01
Primary Industry
Distributors (Healthcare)
Other Industries
Discovery Tools (Healthcare)
Other Devices and Supplies
Corporate Office
  • 155 Rue D Eragny
  • 95000 Neuville sur Oise
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hyphen BioMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hyphen BioMed‘s full profile, request access.

Request a free trial

Hyphen BioMed Patents

Hyphen BioMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-2908892-A1 Chromogenic determination of factor viii:c activity, comprises adding substance comprising at least one metal ion except calcium ion, potentiating the determination of the factor viii:c activity, identified as being present in plasma Active 21-Nov-2006
FR-2908892-B1 Process for the chromogenic assay of factor viii: c activity and need for chromogenic assay of factor viii: c activity in plasmas or therapeutic fractions Inactive 21-Nov-2006
US-20100015647-A1 Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pahtologies potentiated by heparin such as heparin-induced thrombocytopenia Active 23-Jun-2006
AU-2007262869-A1 Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia Inactive 23-Jun-2006
CA-2655582-A1 Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia Active 23-Jun-2006 G01N33/86
To view Hyphen BioMed’s complete patent history, request access »

Hyphen BioMed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hyphen BioMed Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hyphen BioMed‘s full profile, request access.

Request a free trial

Hyphen BioMed FAQs

  • When was Hyphen BioMed founded?

    Hyphen BioMed was founded in 1999.

  • Where is Hyphen BioMed headquartered?

    Hyphen BioMed is headquartered in Neuville sur Oise, France.

  • What is the size of Hyphen BioMed?

    Hyphen BioMed has 100 total employees.

  • What industry is Hyphen BioMed in?

    Hyphen BioMed’s primary industry is Distributors (Healthcare).

  • Is Hyphen BioMed a private or public company?

    Hyphen BioMed is a Private company.

  • What is Hyphen BioMed’s current revenue?

    The current revenue for Hyphen BioMed is .

  • Who are Hyphen BioMed’s investors?

    IDF Capital and Naxicap Partners have invested in Hyphen BioMed.

  • When was Hyphen BioMed acquired?

    Hyphen BioMed was acquired on 01-Jun-2010.

  • Who acquired Hyphen BioMed?

    Hyphen BioMed was acquired by Sysmex (Diagnostic Equipment).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process